Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.

ABSTRACT:

Background

Alveolar soft part sarcoma (ASPS) is an exceedingly rare and orphan disease, without active drugs approved in the front line. Pazopanib and trabectedin are licensed for sarcoma treatment from second-line, but very little and contradictory data are available on their activity in ASPS. Lacking ongoing and/or planned clinical trials, we conducted a multi-institutional study involving the reference sites for sarcoma in Europe, U.S., and Japan, within the World Sarcoma Network, to investigate the efficacy of pazopanib and trabectedin.

Materials and methods

From May 2007, 14 of the 27 centers that were asked to retrospectively review their databases had identified 44 advanced ASPS patients treated with pazopanib and/or trabectedin. Response was evaluated by Response Eva

SUBMITTER: Stacchiotti S 

PROVIDER: S-EPMC5759809 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature